AXA |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.43 EUR | -0.39% |
|
-0.71% | +3.58% |
| 06-24 | Publicis : Publicis Conseil wins Cannes Lions award | CF |
| 06-21 | German Association of Cities: More houses need natural hazard insurance | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.58% | 72.08B | - | ||
| +8.15% | 50.7B | B | ||
| +7.64% | 50.62B | B+ | ||
| +21.14% | 46.35B | B+ | ||
| +13.41% | 42.23B | B+ | ||
| +22.69% | 38.52B | B | ||
| +16.65% | 33.16B | B | ||
| -3.11% | 28.19B | B | ||
| +30.05% | 26.77B | A | ||
| -10.53% | 26.72B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CS Stock
- AXA Stock
- Ratings AXA
